Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Navenibart by Astria Therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Navenibart is under clinical development by Astria Therapeutics and currently in Phase II for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor...
Risk adjusted net present value: What is the current valuation of Astria Therapeutics's Navenibart?
Navenibart is a monoclonal antibody commercialized by Astria Therapeutics, with a leading Phase II program in Hereditary Angioedema (HAE) (C1...
Risk adjusted net present value: What is the current valuation of Astria Therapeutics's Navenibart?
Navenibart is a monoclonal antibody commercialized by Astria Therapeutics, with a leading Phase II program in Hereditary Angioedema (HAE) (C1...